<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01218672</url>
  </required_header>
  <id_info>
    <org_study_id>PE1006</org_study_id>
    <nct_id>NCT01218672</nct_id>
  </id_info>
  <brief_title>Photoselective Vaporization of the Prostate With the GreenLight XPS™ Laser System vs TURP for the Treatment of BPH</brief_title>
  <official_title>A Prospective Multicenter Randomized Study Comparing Photoselective Vaporization of the Prostate With the GreenLight XPS™ Laser System and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study compares procedural and post procedural outcomes for photoselective vaporization of&#xD;
      the prostate (PVP) and transurethral resection of the prostate (TURP) for the treatment of&#xD;
      lower urinary tract symptoms due to benign prostatic enlargement causing bladder outlet&#xD;
      obstruction. The study requires use of the CE marked GreenLight XPS™ Laser System (GreenLight&#xD;
      XPS) or a CE marked monopolar or bipolar loop TURP system for the treatment of benign&#xD;
      prostatic hyperplasia (BPH).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will compare procedural and post procedural outcomes for photoselective&#xD;
      vaporization of the prostate (PVP) and transurethral resection of the prostate (TURP) for the&#xD;
      treatment of lower urinary tract symptoms due to benign prostatic enlargement causing bladder&#xD;
      outlet obstruction. The study requires use of the CE marked GreenLight XPS™ Laser System&#xD;
      (GreenLight XPS) or a CE marked monopolar or bipolar loop TURP system for the treatment of&#xD;
      benign prostatic hyperplasia (BPH). The purpose of the study is to demonstrate that PVP is&#xD;
      not inferior to TURP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>International Prostate Symptom Score (IPSS)</measure>
    <time_frame>6 months</time_frame>
    <description>The IPSS is a patient-administered 7-question instrument used to classify severity of benign prostatic hyperplasia symptoms (BPH). Total scores can range from 0 to 35 (asymptomatic to very symptomatic).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Urinary Flow Rate (Qmax)</measure>
    <time_frame>6 months</time_frame>
    <description>Qmax measured from a void of at least 150 ml in volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From Complications</measure>
    <time_frame>180 days</time_frame>
    <description>A complication is defined as a device or procedure-related adverse event meeting at least 1 of the following criteria: Perforation of tissue or a physiologic structure; Required a prolonged or secondary hospitalization; Required surgical or invasive intervention (e.g., breaking of the skin) and excluding urinary catheterization for transient retention lasting less than 7 days and/or IV medications related to anesthesia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate Volume</measure>
    <time_frame>6 months</time_frame>
    <description>Prostate volume measured via transrectal ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post Treatment Outcomes of PVP and TURP</measure>
    <time_frame>3 weeks post treatment</time_frame>
    <description>Short Form Health Survey (SF-36 Acute) collected at 3-week visit. The SF-36 is a multi-purpose, short-form, health survey of functional health and well-being scores in a three-section format: Utility Index (score = 0-1 with higher score being better); Physical Component Summary (PCS) comprising of physical functioning, role-physical, bodily pain, and overall general health; Mental Component Summary (MCS) comprising of vitality, social functioning, role-emotional, and mental health. Each component in the PCS and MCS sections have a score of 1-100 with the higher score being better. The acute version uses a 1-week recall period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immediate Post Treatment Outcomes of PVP and TURP</measure>
    <time_frame>3 weeks</time_frame>
    <description>Length of stay calculated as the difference from entering the recovery room date/time to discharge date/time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Status of PVP and TURP</measure>
    <time_frame>Baseline and 24-months</time_frame>
    <description>The IPSS, OABq, SF-36 Health Summary and EQ-5D instruments will be scored. IPSS classifies voiding symptoms with scores from 0-35 (asymptomatic to very symptomatic). The OABq captures overactive bladder symptom bother with scores from 0-100 (lower score is better). The SF-36 is a health survey with scores from 1-100 (higher score is better). EQ-5D assesses health status across a range of conditions and treatments with a score of 0-1 (higher score is better).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of PVP and TURP Assessed Using International Index of Erectile Function (IIEF-5) and International Consultation on Incontinence Questionnaire - Short Form (ICIQ-SF)</measure>
    <time_frame>Baseline, 12-months, and 24-months</time_frame>
    <description>The International Index of Erectile Function (IIEF-5) and International Consultation on Incontinence Questionnaire - Short Form (ICIQ-SF) instruments will be collected at baseline and the follow-up visits.&#xD;
The IIEF-5 is a self-administered 5 question instrument that assesses the relevant domains of male sexual function such as erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction with a total possible score of 5-25 (higher score is better).&#xD;
The ICIQ-SFis a self-administered 4-question tool designed for the assessment and quantification of incontinence and its impact on quality of life during the previous 4 weeks with a total score of 0-21 (higher score is worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Satisfaction of PVP and TURP</measure>
    <time_frame>3-weeks, 3-months, 6-months, 12-months, and 24-months</time_frame>
    <description>Subject responses to satisfaction with treatment as collected on follow-up visits.&#xD;
Data presented below indicates responses from subjects that would go through study treatment again at each of the defined follow-up visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Retreatment of PVP and TURP</measure>
    <time_frame>2 Years</time_frame>
    <description>Subject experiencing a retreatment (removal of tissue via TUPR, PVP, or other intervention) for obstruction after the initial procedure was required</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">291</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>GreenLight XPS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Photoselective vaporization of the prostate using GreenLight XPS laser system.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transurethral Resection of the Prostate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Monopolar and bipolar Transuretheral resection of the prostate (TURP)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Photoselective Vaporization of the Prostate</intervention_name>
    <description>GreenLight XPS laser console GreenLight XPS consists of a 532 nm laser console capable of achieving power outputs between 20W and 180W. Laser technology is used to vaporize tissue for debulking prostatic hyperplasia and improvement of lower urinary tract symptoms. The 532 nm wavelength is in the visible spectrum as green light and is strongly absorbed by oxyhemoglobin.&#xD;
GreenLight XPS will be used in conjunction with the MoXy™ fiber. The fiber features a side firing mechanism delivering up to180W of 532 nm light to vaporize and coagulate the prostate tissue. The fiber is guided to the treatment site by the continuous flow cystoscope, consisting of an inner and outer sheath set, 30ْ forward oblique telescope and visual obturator.</description>
    <arm_group_label>GreenLight XPS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transurethral Resection of the Prostate</intervention_name>
    <description>Monopolar and bipolar loop TURP Systems The TURP procedure requires the use of a resectoscope, camera system and irrigation fluid. The system consists of a generator unit and a wire loop with an electrical current running through the loop used to cut prostate tissue and cauterize. Prostate tissue is cut away in small pieces and removed at the end of the procedure using irrigation. There are many manufacturers of TURP systems. Any monopolar and bipolar loop system that carry the CE mark may be used for the study.</description>
    <arm_group_label>Transurethral Resection of the Prostate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Subject has provided informed consent and agrees to attend all study visits&#xD;
&#xD;
          -  Subject has diagnosis of lower urinary tract symptoms due to benign prostatic&#xD;
             enlargement causing bladder outlet obstruction&#xD;
&#xD;
          -  Subject is willing to be randomized&#xD;
&#xD;
          -  Subject is able to complete self-administered questionnaires&#xD;
&#xD;
          -  Clinical investigator has documented in the subject's medical record that in his/her&#xD;
             judgment the subject is a surgical candidate for either the PVP or the TURP procedure&#xD;
             and may be randomized into either arm&#xD;
&#xD;
          -  Subject is 40 to 80 years of age&#xD;
&#xD;
          -  Subject has an IPSS score greater than or equal to 12 measured at the baseline visit&#xD;
&#xD;
          -  Subject has medical record documentation of a maximum urinary flow rate (Qmax) less&#xD;
             than 15ml/s (If uroflow testing documentation is available within 90 days prior to the&#xD;
             informed consent date, and the sample is greater than or equal to 150ml, and the Qmax&#xD;
             is less than 15ml/s it may be used for the inclusion/exclusion criteria)&#xD;
&#xD;
          -  Subject has medical record documentation of a prostate volume of less than or equal to&#xD;
             100g by transrectal ultrasound (TRUS) (If TRUS testing documentation is available from&#xD;
             less than 180 days prior to the informed consent date and the prostate volume is less&#xD;
             than or equal to 100g, it may be used for the inclusion/exclusion criteria)&#xD;
&#xD;
          -  Subject is classified as American Society of Anesthesiologists (ASA) I, II or III&#xD;
&#xD;
          -  Subject has a serum creatinine that is within the normal range for the laboratory at&#xD;
             the study center (or documentation of clinical insignificance in the subject's medical&#xD;
             record by the investigator if outside the normal range) and measured less than or&#xD;
             equal to 30 days prior to the date of surgery.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Subject has a life expectancy of less than 2 years&#xD;
&#xD;
          -  Subject is currently enrolled in, or plans to enroll in, any concurrent drug or device&#xD;
             study unless preapproved by the sponsor&#xD;
&#xD;
          -  Subject has an active infection (eg, urinary tract infection or prostatitis)&#xD;
&#xD;
          -  Subject has a diagnosis of, or has received treatment for, chronic prostatitis or&#xD;
             chronic pelvic pain syndrome (eg, non-bacterial chronic prostatitis)&#xD;
&#xD;
          -  Subject has been diagnosed with a urethral stricture or bladder neck contracture&#xD;
             within the 180 days prior to the informed consent date&#xD;
&#xD;
          -  Subject has been diagnosed with 2 or more urethral strictures and/or bladder neck&#xD;
             contractures within the 5 years prior to the informed consent date&#xD;
&#xD;
          -  Subject has a diagnosis of lichen sclerosus&#xD;
&#xD;
          -  Subject has a neurogenic bladder or other neurological disorder that would impact&#xD;
             bladder function (eg, multiple sclerosis, Parkinson's disease, spinal cord injuries)&#xD;
&#xD;
          -  Subject has a diagnosis of polyneuropathy (eg, diabetic)&#xD;
&#xD;
          -  Subject has history of lower urinary tract surgery (eg, TURP, laser, urinary&#xD;
             diversion, artificial urinary sphincter, penile prosthesis)&#xD;
&#xD;
          -  Subject has diagnosis of stress urinary incontinence that requires treatment or daily&#xD;
             pad/device use&#xD;
&#xD;
          -  Subject has a history of intermittent self catheterization&#xD;
&#xD;
          -  Subject has been catheterized or has a PVR &gt;400mls in the 14 days prior to the&#xD;
             surgical procedure&#xD;
&#xD;
          -  Subject has current diagnosis of bladder stones&#xD;
&#xD;
          -  Subject has diagnosis of prostate cancer&#xD;
&#xD;
          -  Subject has a history of CIS, TaGII, TaGIII or any T1 stage bladder cancer&#xD;
&#xD;
          -  Subject has damage to external urinary sphincter&#xD;
&#xD;
          -  Subject has a medical contraindication for undergoing either TURP or PVP surgery (eg,&#xD;
             infection, coagulopathy or significant cardiac or other medical risk factors for&#xD;
             surgery)&#xD;
&#xD;
          -  Subject has a disorder of the coagulation cascade (eg, hemophilia) or disorders that&#xD;
             affect platelet count or function (eg, Von Willebrand's disease) that would put the&#xD;
             subject at risk for intraoperative or postoperative bleeding&#xD;
&#xD;
          -  Subject is unable to discontinue anticoagulant and antiplatelet therapy preoperatively&#xD;
             (3-5 days) except for low dose aspirin (eg, less than or equal to 100mg)&#xD;
&#xD;
          -  Subject has had an acute myocardial infarction, open heart surgery or cardiac arrest&#xD;
             less than 180 days prior to the date of informed consent&#xD;
&#xD;
          -  Subject is immunocompromised (eg, organ transplant, leukemia)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Bachman, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Thomas, MBBCh, FRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess of Wales Hospital, Bridgend Mid Glamorgan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Schwestern Linz</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Maria Middelares Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nouvel Hopital Civil de Strasbourg</name>
      <address>
        <city>Strasbourg Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bretonneau</name>
      <address>
        <city>Tours Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Campus Bejamin Franklin Hindenburgdamm</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UroForshungs GmbH, im St. hedwig Krankenhaus</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Nordwest</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital University of Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Schleswig-Holstein, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakoniekrankenhaus Rotenburg (W.) gGmbH</name>
      <address>
        <city>Rotenburg (Wumme)</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unita di chirurgia Urologica mininvasiva,Azienda Ospedatiera Sant'Andrea Hospital</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZGT Almelo</name>
      <address>
        <city>Almelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RadBound University Njmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB Nijmegen</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Iniversitario Fundacion Alcorcon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Manacor</name>
      <address>
        <city>Manacor</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frimley Park Hospital</name>
      <address>
        <city>Frimley</city>
        <state>Camberley Surrey</state>
        <zip>GU16 7UJ- UK</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brighton and Sussex University Hospitals NHS Trust</name>
      <address>
        <city>Brighton</city>
        <state>East Sussex</state>
        <zip>BN2 1EX UK</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Basingstoke and North Hampshire NHS Foundation Trust</name>
      <address>
        <city>Basingstoke</city>
        <state>Hampshire</state>
        <zip>RG24 9NA, UK</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess of Wales Hospital</name>
      <address>
        <city>Mid Glamorgan</city>
        <state>Wales UK</state>
        <zip>CF31 1RQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Yorkshire NHS Trust Dewsbury &amp; District Hospital</name>
      <address>
        <city>Dewsbury</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kent and Canterbury Hospital</name>
      <address>
        <city>Kent</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings's College Hospital</name>
      <address>
        <city>London,</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whipps Cross University Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 8, 2010</study_first_submitted>
  <study_first_submitted_qc>October 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2010</study_first_posted>
  <results_first_submitted>February 4, 2016</results_first_submitted>
  <results_first_submitted_qc>September 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 3, 2020</results_first_posted>
  <last_update_submitted>September 1, 2020</last_update_submitted>
  <last_update_submitted_qc>September 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BPH</keyword>
  <keyword>Benign Prostatic Hyperplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Ten subjects were determined to be ineligible for the study procedure and were withdrawn before randomization (i.e., study procedure not performed).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GreenLight XPS</title>
          <description>Photoselective vaporization of the prostate using GreenLight XPS Laser System.</description>
        </group>
        <group group_id="P2">
          <title>TURP</title>
          <description>Monopolar and bipolar loop TURP Systems</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="139"/>
                <participants group_id="P2" count="142"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="136"/>
                <participants group_id="P2" count="133"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
                <participants group_id="P2" count="121"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GreenLight XPS</title>
          <description>Photoselective vaporization of the prostate using GreenLight XPS laser system.&#xD;
GreenLight XPS vs. TURP: GreenLight XPS laser console GreenLight XPS consists of a 532 nm laser console capable of achieving power outputs between 20W and 180W. Laser technology is used to vaporize tissue for debulking prostatic hyperplasia and improvement of lower urinary tract symptoms. The 532 nm wavelength is in the visible spectrum as green light and is strongly absorbed by oxyhemoglobin.</description>
        </group>
        <group group_id="B2">
          <title>TURP</title>
          <description>Monopolar and bipolar Transuretheral resection of the prostate (TURP)&#xD;
The TURP procedure requires the use of a resectoscope, camera system and irrigation fluid. The system consists of a generator unit and a wire loop with an electrical current running through the loop used to cut prostate tissue and cauterize. Prostate tissue is cut away in small pieces and removed at the end of the procedure using irrigation. There are many manufacturers of TURP systems. Any monopolar and bipolar loop system that carry the CE mark may be used for the study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="136"/>
            <count group_id="B2" value="133"/>
            <count group_id="B3" value="269"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.2" spread="6.8"/>
                    <measurement group_id="B2" value="66.7" spread="6.6"/>
                    <measurement group_id="B3" value="67.0" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants who were treated</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>International Prostate Symptom Score (IPSS)</title>
        <description>The IPSS is a patient-administered 7-question instrument used to classify severity of benign prostatic hyperplasia symptoms (BPH). Total scores can range from 0 to 35 (asymptomatic to very symptomatic).</description>
        <time_frame>6 months</time_frame>
        <population>The analysis includes all subjects who received a study treatment and for whom the outcome measure is available. Subjects were analyzed according to treatment received (as-treated analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>GreenLight XPS</title>
            <description>Photoselective vaporization of the prostate using GreenLight XPS Laser System.</description>
          </group>
          <group group_id="O2">
            <title>TURP</title>
            <description>Monopolar and bipolar loop TURP Systems</description>
          </group>
        </group_list>
        <measure>
          <title>International Prostate Symptom Score (IPSS)</title>
          <description>The IPSS is a patient-administered 7-question instrument used to classify severity of benign prostatic hyperplasia symptoms (BPH). Total scores can range from 0 to 35 (asymptomatic to very symptomatic).</description>
          <population>The analysis includes all subjects who received a study treatment and for whom the outcome measure is available. Subjects were analyzed according to treatment received (as-treated analysis).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="5.2"/>
                    <measurement group_id="O2" value="5.6" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Urinary Flow Rate (Qmax)</title>
        <description>Qmax measured from a void of at least 150 ml in volume.</description>
        <time_frame>6 months</time_frame>
        <population>The analysis includes all subjects who received a study treatment and for whom the outcome measure is available. Subjects were analyzed according to treatment received (as-treated analysis).</population>
        <group_list>
          <group group_id="O1">
            <title>GreenLight XPS</title>
            <description>Photoselective vaporization of the prostate using GreenLight XPS Laser System.</description>
          </group>
          <group group_id="O2">
            <title>TURP</title>
            <description>Monopolar and bipolar loop TURP Systems</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Urinary Flow Rate (Qmax)</title>
          <description>Qmax measured from a void of at least 150 ml in volume.</description>
          <population>The analysis includes all subjects who received a study treatment and for whom the outcome measure is available. Subjects were analyzed according to treatment received (as-treated analysis).</population>
          <units>ml/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" spread="10.1"/>
                    <measurement group_id="O2" value="24.3" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From Complications</title>
        <description>A complication is defined as a device or procedure-related adverse event meeting at least 1 of the following criteria: Perforation of tissue or a physiologic structure; Required a prolonged or secondary hospitalization; Required surgical or invasive intervention (e.g., breaking of the skin) and excluding urinary catheterization for transient retention lasting less than 7 days and/or IV medications related to anesthesia.</description>
        <time_frame>180 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GreenLight XPS</title>
            <description>Photoselective vaporization of the prostate using GreenLight XPS Laser System.</description>
          </group>
          <group group_id="O2">
            <title>TURP</title>
            <description>Monopolar and bipolar loop TURP Systems</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From Complications</title>
          <description>A complication is defined as a device or procedure-related adverse event meeting at least 1 of the following criteria: Perforation of tissue or a physiologic structure; Required a prolonged or secondary hospitalization; Required surgical or invasive intervention (e.g., breaking of the skin) and excluding urinary catheterization for transient retention lasting less than 7 days and/or IV medications related to anesthesia.</description>
          <units>percentage of patients complication free</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.3"/>
                    <measurement group_id="O2" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prostate Volume</title>
        <description>Prostate volume measured via transrectal ultrasound</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GreenLight XPS</title>
            <description>Photoselective vaporization of the prostate using GreenLight XPS Laser System.</description>
          </group>
          <group group_id="O2">
            <title>TURP</title>
            <description>Monopolar and bipolar loop TURP Systems</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate Volume</title>
          <description>Prostate volume measured via transrectal ultrasound</description>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0" spread="11.7"/>
                    <measurement group_id="O2" value="20.5" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post Treatment Outcomes of PVP and TURP</title>
        <description>Short Form Health Survey (SF-36 Acute) collected at 3-week visit. The SF-36 is a multi-purpose, short-form, health survey of functional health and well-being scores in a three-section format: Utility Index (score = 0-1 with higher score being better); Physical Component Summary (PCS) comprising of physical functioning, role-physical, bodily pain, and overall general health; Mental Component Summary (MCS) comprising of vitality, social functioning, role-emotional, and mental health. Each component in the PCS and MCS sections have a score of 1-100 with the higher score being better. The acute version uses a 1-week recall period.</description>
        <time_frame>3 weeks post treatment</time_frame>
        <population>A total of 136 subjects underwent GL-XPS and 133 subjects underwent TURP procedures. The SF36 questionnaire is comprised of three sections; available data is:&#xD;
SF36 (PCS): 133 GL-XPS, 129 TURP; SF36 (MHS): 134 GL-XPS, 130 TURP; SF36 Utility Index: 125 GL-XPS, 121 TURP.</population>
        <group_list>
          <group group_id="O1">
            <title>GreenLight XPS</title>
            <description>Photoselective vaporization of the prostate using GreenLight XPS Laser System.</description>
          </group>
          <group group_id="O2">
            <title>TURP</title>
            <description>Monopolar and bipolar loop TURP Systems</description>
          </group>
        </group_list>
        <measure>
          <title>Post Treatment Outcomes of PVP and TURP</title>
          <description>Short Form Health Survey (SF-36 Acute) collected at 3-week visit. The SF-36 is a multi-purpose, short-form, health survey of functional health and well-being scores in a three-section format: Utility Index (score = 0-1 with higher score being better); Physical Component Summary (PCS) comprising of physical functioning, role-physical, bodily pain, and overall general health; Mental Component Summary (MCS) comprising of vitality, social functioning, role-emotional, and mental health. Each component in the PCS and MCS sections have a score of 1-100 with the higher score being better. The acute version uses a 1-week recall period.</description>
          <population>A total of 136 subjects underwent GL-XPS and 133 subjects underwent TURP procedures. The SF36 questionnaire is comprised of three sections; available data is:&#xD;
SF36 (PCS): 133 GL-XPS, 129 TURP; SF36 (MHS): 134 GL-XPS, 130 TURP; SF36 Utility Index: 125 GL-XPS, 121 TURP.</population>
          <units>score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SF36 - PCS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.3" spread="8.1"/>
                    <measurement group_id="O2" value="50.5" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF36 - MHS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="130"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" spread="9.7"/>
                    <measurement group_id="O2" value="50.0" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF36 Utility Index</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                    <count group_id="O2" value="121"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.1"/>
                    <measurement group_id="O2" value="0.7" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immediate Post Treatment Outcomes of PVP and TURP</title>
        <description>Length of stay calculated as the difference from entering the recovery room date/time to discharge date/time</description>
        <time_frame>3 weeks</time_frame>
        <population>A total of 136 subjects underwent GL-XPS and 133 subjects underwent TURP procedures. Length of Stay data available for 134 GL-XPS and 132 TURP subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>GreenLight XPS</title>
            <description>Photoselective vaporization of the prostate using GreenLight XPS Laser System.</description>
          </group>
          <group group_id="O2">
            <title>TURP</title>
            <description>Monopolar and bipolar loop TURP Systems</description>
          </group>
        </group_list>
        <measure>
          <title>Immediate Post Treatment Outcomes of PVP and TURP</title>
          <description>Length of stay calculated as the difference from entering the recovery room date/time to discharge date/time</description>
          <population>A total of 136 subjects underwent GL-XPS and 133 subjects underwent TURP procedures. Length of Stay data available for 134 GL-XPS and 132 TURP subjects.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.5" spread="63.3"/>
                    <measurement group_id="O2" value="97.8" spread="63.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Status of PVP and TURP</title>
        <description>The IPSS, OABq, SF-36 Health Summary and EQ-5D instruments will be scored. IPSS classifies voiding symptoms with scores from 0-35 (asymptomatic to very symptomatic). The OABq captures overactive bladder symptom bother with scores from 0-100 (lower score is better). The SF-36 is a health survey with scores from 1-100 (higher score is better). EQ-5D assesses health status across a range of conditions and treatments with a score of 0-1 (higher score is better).</description>
        <time_frame>Baseline and 24-months</time_frame>
        <population>Table reflects available data at specified time-points</population>
        <group_list>
          <group group_id="O1">
            <title>GreenLight XPS</title>
            <description>Photoselective vaporization of the prostate using GreenLight XPS Laser System.</description>
          </group>
          <group group_id="O2">
            <title>TURP</title>
            <description>Monopolar and bipolar loop TURP Systems</description>
          </group>
        </group_list>
        <measure>
          <title>Health Status of PVP and TURP</title>
          <description>The IPSS, OABq, SF-36 Health Summary and EQ-5D instruments will be scored. IPSS classifies voiding symptoms with scores from 0-35 (asymptomatic to very symptomatic). The OABq captures overactive bladder symptom bother with scores from 0-100 (lower score is better). The SF-36 is a health survey with scores from 1-100 (higher score is better). EQ-5D assesses health status across a range of conditions and treatments with a score of 0-1 (higher score is better).</description>
          <population>Table reflects available data at specified time-points</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline IPSS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2" spread="5.9"/>
                    <measurement group_id="O2" value="21.7" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline OABq</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.2" spread="20.5"/>
                    <measurement group_id="O2" value="42.9" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline SF-36 Health Summary</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="133"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2" spread="7.8"/>
                    <measurement group_id="O2" value="51.9" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline EQ5D</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.843" spread="0.193"/>
                    <measurement group_id="O2" value="0.823" spread="0.219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-Month IPSS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="121"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="6.0"/>
                    <measurement group_id="O2" value="5.9" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-Month OABq</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="126"/>
                    <count group_id="O2" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" spread="16.7"/>
                    <measurement group_id="O2" value="11.9" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-Month SF-36 Health Summary</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.5" spread="8.1"/>
                    <measurement group_id="O2" value="53.2" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-Month EQ5D</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.875" spread="0.194"/>
                    <measurement group_id="O2" value="0.857" spread="0.210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tolerability of PVP and TURP Assessed Using International Index of Erectile Function (IIEF-5) and International Consultation on Incontinence Questionnaire - Short Form (ICIQ-SF)</title>
        <description>The International Index of Erectile Function (IIEF-5) and International Consultation on Incontinence Questionnaire - Short Form (ICIQ-SF) instruments will be collected at baseline and the follow-up visits.&#xD;
The IIEF-5 is a self-administered 5 question instrument that assesses the relevant domains of male sexual function such as erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction with a total possible score of 5-25 (higher score is better).&#xD;
The ICIQ-SFis a self-administered 4-question tool designed for the assessment and quantification of incontinence and its impact on quality of life during the previous 4 weeks with a total score of 0-21 (higher score is worse).</description>
        <time_frame>Baseline, 12-months, and 24-months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GreenLight XPS</title>
            <description>Photoselective vaporization of the prostate using GreenLight XPS laser system.&#xD;
Photoselective Vaporization of the Prostate: GreenLight XPS laser console GreenLight XPS consists of a 532 nm laser console capable of achieving power outputs between 20W and 180W. Laser technology is used to vaporize tissue for debulking prostatic hyperplasia and improvement of lower urinary tract symptoms. The 532 nm wavelength is in the visible spectrum as green light and is strongly absorbed by oxyhemoglobin.&#xD;
GreenLight XPS will be used in conjunction with the MoXy™ fiber. The fiber features a side firing mechanism delivering up to180W of 532 nm light to vaporize and coagulate the prostate tissue. The fiber is guided to the treatment site by the continuous flow cystoscope, consisting of an inner and outer sheath set, 30ْ forward oblique telescope and visual obturator.</description>
          </group>
          <group group_id="O2">
            <title>Transurethral Resection of the Prostate</title>
            <description>Monopolar and bipolar Transuretheral resection of the prostate (TURP)&#xD;
Transurethral Resection of the Prostate: Monopolar and bipolar loop TURP Systems The TURP procedure requires the use of a resectoscope, camera system and irrigation fluid. The system consists of a generator unit and a wire loop with an electrical current running through the loop used to cut prostate tissue and cauterize. Prostate tissue is cut away in small pieces and removed at the end of the procedure using irrigation. There are many manufacturers of TURP systems. Any monopolar and bipolar loop system that carry the CE mark may be used for the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability of PVP and TURP Assessed Using International Index of Erectile Function (IIEF-5) and International Consultation on Incontinence Questionnaire - Short Form (ICIQ-SF)</title>
          <description>The International Index of Erectile Function (IIEF-5) and International Consultation on Incontinence Questionnaire - Short Form (ICIQ-SF) instruments will be collected at baseline and the follow-up visits.&#xD;
The IIEF-5 is a self-administered 5 question instrument that assesses the relevant domains of male sexual function such as erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction with a total possible score of 5-25 (higher score is better).&#xD;
The ICIQ-SFis a self-administered 4-question tool designed for the assessment and quantification of incontinence and its impact on quality of life during the previous 4 weeks with a total score of 0-21 (higher score is worse).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline IIEF-5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" spread="7.6"/>
                    <measurement group_id="O2" value="13.7" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline ICIQ-UI SF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="4.7"/>
                    <measurement group_id="O2" value="4.4" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-Months IIEF-5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" spread="7.5"/>
                    <measurement group_id="O2" value="13.9" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-Months ICIQ-UI SF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="4.1"/>
                    <measurement group_id="O2" value="2.0" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Satisfaction of PVP and TURP</title>
        <description>Subject responses to satisfaction with treatment as collected on follow-up visits.&#xD;
Data presented below indicates responses from subjects that would go through study treatment again at each of the defined follow-up visits.</description>
        <time_frame>3-weeks, 3-months, 6-months, 12-months, and 24-months</time_frame>
        <population>Descriptive statistics including frequency and percentages will be calculated. Results presented below are number of respondents who said Yes.</population>
        <group_list>
          <group group_id="O1">
            <title>GreenLight XPS</title>
            <description>Photoselective vaporization of the prostate using GreenLight XPS Laser System.</description>
          </group>
          <group group_id="O2">
            <title>TURP</title>
            <description>Monopolar and bipolar loop TURP Systems</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Satisfaction of PVP and TURP</title>
          <description>Subject responses to satisfaction with treatment as collected on follow-up visits.&#xD;
Data presented below indicates responses from subjects that would go through study treatment again at each of the defined follow-up visits.</description>
          <population>Descriptive statistics including frequency and percentages will be calculated. Results presented below are number of respondents who said Yes.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Retreatment of PVP and TURP</title>
        <description>Subject experiencing a retreatment (removal of tissue via TUPR, PVP, or other intervention) for obstruction after the initial procedure was required</description>
        <time_frame>2 Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GreenLight XPS</title>
            <description>Photoselective vaporization of the prostate using GreenLight XPS Laser System.</description>
          </group>
          <group group_id="O2">
            <title>TURP</title>
            <description>Monopolar and bipolar loop TURP Systems</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Retreatment of PVP and TURP</title>
          <description>Subject experiencing a retreatment (removal of tissue via TUPR, PVP, or other intervention) for obstruction after the initial procedure was required</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Months 0-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Months 7-12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Months 13-24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the date of the informed consent until the subject exits the study. (Mean follow-up was 23.3 months)</time_frame>
      <desc>Adverse events determined as &quot;Other&quot; were not further defined during analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>GreenLight XPS</title>
          <description>Photoselective vaporization of the prostate using GreenLight XPS Laser System.</description>
        </group>
        <group group_id="E2">
          <title>TURP</title>
          <description>Monopolar and bipolar Transuretheral resection of the prostate (TURP)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Irritative symptoms/pain/discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Stricture</sub_title>
                <description>meatal, urethral, bladder neck</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Urinary Incontinence</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="136"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="136"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="26" subjects_affected="25" subjects_at_risk="136"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Irritative Symptoms/Pain/Discomfort</sub_title>
                <counts group_id="E1" events="33" subjects_affected="30" subjects_at_risk="136"/>
                <counts group_id="E2" events="30" subjects_affected="30" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Stricture (meatal, urethral, bladder neck)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Urinary Incontinence</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="136"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="136"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="136"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Teresa Takle-Flach, Director, Clinical Operations</name_or_title>
      <organization>Boston Scientific Corporation</organization>
      <phone>(952)930-6000</phone>
      <email>teresa.takle-flach@bsci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

